Modus Therapeutics Pauses Phase IIa Enrollment After SUSAR
The company voluntarily paused enrollment in Part 2 of its Phase IIa sevuparin CKD anemia study after a reported SUSAR, shifting the expected proof-of-concept readout to Q1 2027. Cash is expected to fund operations into Q2 2027.
Modus Therapeutics has voluntarily paused enrollment in Part 2 of its Phase IIa sevuparin CKD anemia study following a reported SUSAR. The pause is expected to move the proof-of-concept readout to Q1 2027. The company expects its cash to fund operations into Q2 2027.